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Previewscell survival and apoptosis through the
generation of bioactive lipids (Oskouian
and Saba, 2010).
The new findings have several clinical
implications. The authors propose that
PAFAH1B3 may serve as a useful
prognostic marker in newly diagnosed
patients, and, considering that silencing
PAFAH1B3 in breast cancer cells results
in profound growth inhibition, it may
represent a novel therapeutic target for
breast cancer, especially in high risk
patients harboring tumors positive for
TAZ and/or PAFAH1B3. It will be impor-
tant to determine whether inhibiting the
normal activity of PAFAH1B3 is safe
and well tolerated in humans. Whether
PAFAH1B3 will also be a downstream
mediator of YAP/TAZ in other cancers in
which Hippo has been implicated also re-
mains to be determined.
Although promising, the study raises
several important questions that have
not yet been directly addressed. First,
how does the Hippo pathway influence
PAFAH1B3 activity? Second, is the activ-
ity of PAFAH1B3 fundamental to TAZ’s804 Chemistry & Biology 21, July 17, 2014 ª2ability to confer self-renewal capability to
breast cancer cells? Considering a recent
report demonstrating that Hippo regu-
lates the transition from differentiated to
undifferentiated state in liver cells (Yimla-
mai et al., 2014), it seems likely that a
direct impact on the ‘‘stemness’’ of can-
cer stem cells could be mediated by TAZ
targets. Third, what PAFAH substrates/
products mediate tumorigenicity? Last,
this study identified a number of other
genes and proteins that were differentially
expressed or activated in response to
TAZ overexpression in this cancer pro-
gression model. Although not pursued
by the authors, these targets may be rele-
vant in the biology of breast cancer pro-
gression, and thus additional hypotheses
may emerge from this interesting data set.
In conclusion, Mulvihill et al. (2014) pre-
sent exciting work that opens a new
dimension for cancer research and thera-
peutics. Overall, the intriguing results
demonstrate the utility of metabolism-
focused investigations to dissect the
biology of the cancer cell and identify
new targets.014 Elsevier Ltd All rights reservedREFERENCES
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The tandem bromodomains (BD1 and BD2) of the BET family proteins BRD2, BRD3, BRD4, and BRDT are
structurally conserved but not functionally equivalent. In this issue of Chemistry & Biology, Gacias and
colleagues report that a BD1-specific chemical inhibitor, Olinone, enhances oligodendrocyte differentiation,
contrasting the reverse process triggered by broad BD1/BD2-targeting inhibitors, highlighting distinct roles
of BD1 and BD2 in cell fate decision.The amino acid sequences and 3D struc-
tures of the tandem acetyl-lysine (Kac)-
binding bromodomains (BD1 and BD2)
present in the bromodomain and extra-terminal (ET) domain-containing BET
family proteins are evolutionarily con-
served (Wu and Chiang, 2007; Filippako-
poulos et al., 2012). Nevertheless, thefinding of two additional conserved re-
gions with one containing the N-terminal
cluster of casein kinase II phosphoryla-
tion sites (NPS) and one harboring basic
AB
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Figure 1. Differential Effects of BET Inhibitors on Oligodendrocyte Differentiation
(A) Human BET family proteins. The evolutionarily conserved regions, including bromodomain I (BD1),
bromodomain II (BD2), extraterminal domain (ET), C-terminal motif (CTM), N-terminal cluster of CK2
phosphorylation sites (NPS), and basic residues-enriched interaction domain (BID) are schematized
with conserved N140 and N433 as well as diverged D144 and H437 residues between BD1 and BD2
also indicated. The full-length long (L) and two short (S) forms (a and b) of human BRD4 with common
amino acids 1–719 but different 30 regions generated by alternative splicing are also shown.
(B) Chemical inhibitors targeting BD1 and/or BD2 of BET proteins. BrD1i and BrD2i are respective
BD1-specific and BD2-specific inhibitors, whereas BETi represents broad inhibitors binding to both
BD1 and BD2. Acetylated (Ac) histones and transcription factors (TF) binding to BD1 and/or BD2 are
indicated on the bottom.
(C) BrD1i promotes, but BETi inhibits, oligodendrocyte differentiation. Representative genes expressed
in oligodendrocyte progenitor cells and myelin-producing cells are indicated in respective cells in
parentheses.
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Previewsresidues-enriched interaction domain
(BID) situated downstream of the BD2 in
all the BET family proteins (Figure 1A) pre-
dicts that BD1 and BD2 are differentially
regulatedbyposttranslationalmodification
that, in turn, recruits different partner pro-
teins to regulate BET protein function in
diversecellular processes (Wuet al., 2013).
Using a structure-guided design to syn-
thesize and screen for small compounds
binding selectively to the BD1 of bromo-
domain-containing protein 4 (BRD4), Ga-
cias et al. (2014) identified a high-affinity
compound containing an acetyl moiety
linked by four methylene groups to a tricy-
clic tetrahydro-pyrido indole scaffold that
exhibits over 100-fold higher binding
affinity to BD1 (Kd 3.4 mM) than BD2
(Kd > 300 mM). This compound, named
Olinone, shows comparable binding affin-
ity to BRD2-BD1 and BRD3-BD1 and
equal reluctance of association with the
second bromodomains of the other BET
proteins. Olinone occupies the hydropho-
bic Kac-binding pocket in a configuration
and surface contact similar to that seen
with a diacetyl histone H4 lysine 5 (K5)
and lysine 8 (K8) peptide binding to
BRD4-BD1, as revealed by X-ray crystal-
lography at 0.94 A˚. Although the aspara-
gine 140 (N140) residue of BD1 crucial
for contacting Kac and Olinone is likewise
present in BD2 (N433, Figure 1A), a non-
conserved histidine residue (H437) at BD2
poses a steric clash for Olinone contact
complementarily mediated by aspartate
144 (D144) at the comparable position
in BRD4-BD1. This structural insight
elegantly explains the binding selectivity
of Olinone for the BD1 of BET proteins.
Conversely, H437 provides crucial con-
tacts with the K73/K76-diacetylated Twist
transcription factor that recruits BRD4
via BD2-specific association to enhance
epithelial-to-mesenchymal transition in
basal-like breast cancer cells, and con-
version of D144 to histidine allows BD1
interaction with acetylated Twist (Shi
et al., 2014), further highlighting the
importance of BD1-specific D144 and
BD2-specific H437 for bromodomain
selectivity in drug design and recruitment
of transcription factors. Other than Twist,
the structural similarity for BET bromodo-
main binding to acetylated histone tails
and acetylated nonhistone proteins has
also been illustrated with BRD3-BD1-
specific contact with K312/K315-diacety-
lated hematopoietic transcription factorª2014 Elsevier Ltd All rights reserved 805
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PreviewsGATA1 (Gamsjaeger et al., 2011) and
individual BD1 and BD2 of BRD4 asso-
ciation with the K310-acetylated RelA
subunit of inflammatory transcription fac-
tor NF-kB (Zou et al., 2014).
The availability of BD1-selective chemi-
cal inhibitor (BrD1i) Olinone, distinct from
the previously characterized broad BET
inhibitors (BETi) MS417, JQ1, and I-BET
that target both BD1 and BD2 and a
BD2-selective inhibitor (BrD2i) MS765/
RVX-208 (Figure 1B), allows the use of
these pharmacological agents to address
the target selectivity and functional sig-
nificance of BD1 and BD2. Using mouse
oligodendrocyte progenitor cells (OPCs)
that can differentiate into myelin-produc-
ing oligodendrocytes, Gacias et al. (2014)
found that treating OPCs with Olinone
promotes oligodendrocyte differentiation,
as reflected by enhanced myelin-specific
Mag,Mog, andMbp gene expression, ac-
companied by reduced progenitor Hes1,
Hes5, and Gmnn marker expression; but,
surprisingly, treating oligodendrocytes
with broad BET inhibitors such as MS417
that target both BD1 and BD2 actually
hinders differentiation (Figure 1C). This
observation was further confirmed via the
use of additional bromodomain-selective
BET inhibitors, including MS611 BrD1i
and RVX-208/MS765 BrD2i (Figure 1B).
Enhanced myelin formation by BrD1i,
but not BrD2i and BETi, highlights the806 Chemistry & Biology 21, July 17, 2014 ª2need to developmore selective bromodo-
main inhibitors to enrich our molecular
understanding of BD1- and BD2-specific
function in gene targeting and disease
treatment. It would be interesting to deter-
mine whether oligodendrocyte lineage
gene expression is indeed regulated by
BRD2 that is predominantly expressed
in these cells and whether BRD4 and
BRD3 could independently or collabora-
tively regulate progenitor and differenti-
ated oligodendrocyte gene expression
with BRD2. The existence of other evolu-
tionarily conserved regions (e.g., ET,
NPS, and BID) that regulate chromatin
binding and partner association of the
BET family proteins also predicts new
drug development targeting other func-
tionally important regions of the BET
proteins. The recent finding that many
protein kinase inhibitors targeting PLK1
(e.g., BI-2536), JAK2 (e.g., TG-101209
and TG-101348), PI3K (e.g., LY294002
and LY303511), and other kinases also
exhibit strong binding affinity to both
BD1 and BD2 or specifically to BD1
(Ciceri et al., 2014; Dittmann et al., 2014;
Ember et al., 2014; see Figure 1B) raises
not only interest in developing dual
kinase/BET inhibitors for cancer thera-
peutics but also concerns of off-target
effects that require further mechanistic
studies of drug action in various biological
systems.014 Elsevier Ltd All rights reservedREFERENCES
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In this issue of Chemistry & Biology, Kim and colleagues describe their work on optogenetic control of fibro-
blast growth factor receptor (FGFR) signaling. By engineering a chimeric receptor, the authors demonstrate
that FGFR intracellular signaling can be controlled in space and time by blue light.Intracellular signal transduction transmits
external signals into the cell interior to
ensure proper cellular decision making.
Fibroblast growth factor receptor (FGFR)
signaling belongs to a classical family
of signal transduction pathways thatregulates a wide spectrum of biological
events such as development, wound
healing, and angiogenesis. Dysregulation
of FGFR signaling has been associ-
ated with developmental disorders and
cancers.Puzzlingly, many of the key cellular
signaling modules initiated by mem-
brane-bound receptor tyrosine kinases,
like FGFR, activate overlapping sets
of downstream pathways, but with dis-
tinct outcomes. Consequently, a central
